Bonne Santé Group Executes Acquisition Agreement With Nutraceutical Manufacturing Facility
Acquisition to Represent Threshold Event for Company's Global CBD Initiative
MIAMI, November 2, 2017 (Newswire.com) - Bonne Santé Group, Inc. (“BSG” or the “Company”), an early stage global nutraceutical company, announced today that it has executed a definitive acquisition agreement to acquire a Florida-based state-of-the-art FDA-approved nutraceutical manufacturing facility. The announcement was made by William W. Nicholson, Executive Chairman of Bonne Santé Group.
“We are pleased to announce the execution of this acquisition agreement, which represents a milestone event for our various initiatives,” stated Mr. Nicholson. “On completion of this initial acquisition, Bonne Santé will be able to accelerate development and expansion of our product portfolio, manufacturing capacity and distribution channels. BSG's holding-company structure will enable the Company to launch distribution and sales quickly, while realizing savings and other cost-efficiencies through consolidation and elimination of dependency on third-party manufacturers.”
Bonne Santé Group’s mission is the creation of a world-class nutraceutical company engaged in the development, manufacturing and sale of quality nutraceutical and related health and lifestyle products for distribution to an expanding marketplace with a heavy emphasis on industrial hemp-derived CBD (cannabidiol) manufacturing and sales worldwide.
Mr. Nicholson concluded, “We expect this acquisition to provide us with maximum flexibility for product diversification and risk management, in addition to providing us with additional prospects as we move into new markets while also addressing a wide range of novel product opportunities, especially in this high-growth industry.”
Among other conditions to closing of the acquisition are a number of events including, but not limited to, the completion of due diligence and financing for the acquisition, as well as various other considerations laid out in the acquisition agreement and attendant documents.
About Bonne Santé Group, Inc.
Bonne Santé Group, Inc. is an early stage Delaware corporation incorporated on February 8, 2017. Structured as a holding company, BSG intends to execute a buy and build strategy with serial accretive acquisitions. BSG intends to engage in the acquisition, operation and sale of a broad spectrum of nutraceutical and related products. To drive growth and earnings, the Company will develop proprietary products as well as acquire other brands. The Company is positioning itself as a dominant force in the burgeoning industrial hemp-derived CBD sector, which is seeing significant consumer demand. The management team and the board of directors of Bonne Santé have an objective of creating a major international nutraceutical and related products company targeting a minimum of $250 to $500 million in revenues within the first three years following the initial acquisition, manufacturing and marketing a wide range of world-class nutraceutical products and next-generation delivery technologies.
Certain matters discussed within this press release are forward-looking statements. Although Bonne Santé Group believes the expectations reflected in such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Bonne Santé Group does not undertake any duty to update any statements contained herein (including any forward-looking statements), except as required by law. No assurances can be made that Bonne Santé Group will successfully acquire its acquisition targets. Factors that could cause actual results to differ materially from expectations include general industry considerations, regulatory changes, changes in local or national economic conditions and other risks.
Bonne Santé Group, Inc.
990 Biscayne Blvd., Suite 1002
Source: Bonne Santé Group, Inc.